ANNEXON, INC.
Moat Score — Annexon, Inc.
Total Moat Score
13 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | Annexon holds patent protection on its anti-C1q antibodies and antibody fragments, along with clinical and regulatory know-how (orphan drug and breakthrough designations) built around a distinctive complement biology platform, giving it real but time-limited intellectual property protection. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | As a clinical-stage biotech with no commercial manufacturing scale yet, Annexon has no structural cost advantage versus larger, better-capitalized complement-focused rivals such as Apellis or Alexion/AstraZeneca. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 4 / 5 | If approved in Guillain-Barre syndrome, Annexon would likely command significant orphan-drug pricing power given the absence of any approved disease-modifying alternative and the severity of the condition, though payers would still scrutinize price against IVIg/plasma exchange costs. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | A biopharmaceutical therapy exhibits no network effect - its value to one patient or physician is unrelated to how many others use it. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Once a physician and patient commit to a treatment course for an acute condition like GBS there is limited need to switch mid-course, but switching costs are low pre-prescription since prescribers can readily choose among available options for any given patient. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | Guillain-Barre syndrome is rare enough that the total addressable patient population may not support multiple heavily-invested competing branded therapies, giving a first approved entrant like Annexon some efficient-scale protection in that specific niche. |